Showing 2261-2270 of 6036 results for "".
- Alcon Canada introduces PRECISION1 Contact Lenseshttps://modernod.com/news/alcon-canada-introduces-precision1-contact-lenses/2478144/Alcon has launched the PRECISION1 daily disposable, silicone hydrogel (SiHy) contact lenses in Canada. Designed to address the common issues that cause 1-in-5 new wearers to discontinue contact lens within the first year (poor vision, comfort and handling issues1), Precision1 he
- Gyroscope Announces Appointment of Leaders in Retinal Disease, Gene Therapy and the Complement System to Advisory Boardshttps://modernod.com/news/gyroscope-announces-appointment-of-leaders-in-retinal-disease-gene-therapy-and-the-complement-system-to-advisory-boards/2478130/Gyroscope Therapeutics announced the appointment of leading experts in retinal disease, gene therapy, and the complement system to its Clinical and Scientific advisory boards. The newly appointed boards will help guide the development of the company’s lead investigational gene therapy, GT00
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Hanita Lenses Announces Launch of Intensity IOLhttps://modernod.com/news/hanita-lenses-announces-launch-of-intensity-iol/2478082/After 3 years of development, Israel-based Hanita Lenses announced the launch of the Intensity IOL. The Intensity is a presbyopia-correcting IOL that has been developed by employing a proprietary iterative algorithm—called the Dynamic Light Utilization (DLU) technology—for better light eff
- Norlase Announces CE Mark Approval for LEAF Green Laserhttps://modernod.com/news/norlase-announces-ce-mark-approval-for-leaf-green-laser/2478045/Norlase announced that it has been granted the CE Mark approval for the LEAF, a first in class, fiberless green laser for the treatment of retina and glaucoma diseases. The CE Mark follows the recent FDA 510(k) market clearance of the LEAF and ISO 13485:2016 certification of Norlase’s medical dev
- Senate Democrats Demand $25 Billion for Widespread COVID-19 Vaccine Distributionhttps://modernod.com/news/senate-democrats-demand-25-billion-for-widespread-covid-19-vaccine-distribution/2478013/Senate Democrats want to pass legislation that provides $25 billion to ensure a potential COVID-19 vaccine is heavily distributed among the U.S. population, according to a FierceHealthcare
- Santen and NTC Release Results of Phase 3 Clinical Study Examining 7-Day Fixed Dose Combination of Levofloxacinhttps://modernod.com/news/santen-and-ntc-release-results-of-phase-3-clinical-study-examining-7-day-fixed-dose-combination-of-levofloxacin/2478007/Santen EMEA and NTC have announced that the results of their phase 3 clinical study, LEADER7, have been published in Eye. The study demonstrated for the first time that 7-day levofloxacin/dexamethasone eye dr
- Santen and NTC Announce Positive Outcome of European Decentralised Procedure (DCP) for Ducressa Post-Cataract Surgery Antibiotic/Steroid Combinationhttps://modernod.com/news/santen-and-ntc-announce-positive-outcome-of-for-ducressa-post-cataract-surgery-antibiotic-steroid-combination/2477944/Santen EMEA and NTC, have announced the completion and positive outcome of the European Decentralised Procedure (DCP) for a fixed dose combination of levofloxacin and dexamethasone (Ducressa), offering reduced exposure to antibiotics following cataract surgery.1 Levofloxacin is a broa
- Leo Lens Pharma Lead Asset Ready for Human Clinical Evaluationhttps://modernod.com/news/leo-lens-pharma-lead-asset-ready-for-human-clinical-evaluation/2477927/Leo Lens Pharma has announced that its lead asset, LL-BMT1, is ready for IND submission and human clinical evaluation. LL-BMT1 is a therapeutic contact lens that delivers preservative-free bimatoprost to the eye to treat glaucoma for 1 week. After a pre-IND meeting with the FDA, Leo Lens has now
- Bausch + Lomb Receives FDA Clearance for Infuse Daily Disposable Silicone Hydrogel Contact Lenseshttps://modernod.com/news/bausch-lombs-infuse-daily-disposable-silicone-hydrogel-contact-lenses-receive-fda-510k-clearance-for/2477862/Bausch + Lomb has received 510(k) clearance from the FDA for the Bausch + Lomb Infuse daily disposable silicone hydrogel (SiHy daily) contact lenses. Bausch + Lomb Infuse contact lenses feature a next generation contact lens material (kalifilcon A), which is designed to meet the unmet need